U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H10FN3O3S
Molecular Weight 247.2481
Optical Activity ( - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EMTRICITABINE

SMILES

c1c(c(=N)nc(n1[C@]2([H])CS[C@]([H])(CO)O2)O)F

InChI

InChIKey=XQSPYNMVSIKCOC-NTSWFWBYSA-N
InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1

HIDE SMILES / InChI

Molecular Formula C8H10FN3O3S
Molecular Weight 247.2481
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: http://www.emory.edu/news/Releases/emtri/

Emtricitabine was discovered by Emory researchers Dr. Dennis C. Liotta, Dr. Raymond F. Schinazi and Dr. Woo-Baeg Choi and licensed to Triangle Pharmaceuticals by Emory University in 1996. Triangle was acquired by Gilead in 2003. Emtricitabine, marketed by Gilead as Emtriva, was first approved by the U.S. Food and Drug Administration in July 2003 for the treatment of HIV infection in combination with other antiretroviral agents. Emtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits the activity of the HIV-1 reverse transcriptase by competing with the natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA which results in chain termination.

Originator

Curator's Comment:: Liotta, Schinazi and Choi (Emory University) and licensed to Triangle Pharmaceuticals by Emory University in 1996

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
EMTRIVA

Approved Use

EMTRIVA is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection. Additional important information regarding the use of EMTRIVA for the treatment of HIV-1 Infection: • EMTRIVA should not be coadministered with ATRIPLA™, TRUVADA®, or Lamivudine-containing products (see WARNINGS). • In treatment-experienced patients, the use of EMTRIVA should be guided by laboratory testing and treatment history (see MICROBIOLOGY).

Launch Date

1057104000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.8 μg/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EMTRICITABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.7 μg/mL
5.6 mg/kg 1 times / day steady-state, oral
dose: 5.6 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EMTRICITABINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10 μg × h/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EMTRICITABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
12.6 μg × h/mL
5.6 mg/kg 1 times / day steady-state, oral
dose: 5.6 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EMTRICITABINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10 h
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EMTRICITABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.2 h
5.6 mg/kg 1 times / day steady-state, oral
dose: 5.6 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EMTRICITABINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
96%
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EMTRICITABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 26 - 42 years
Health Status: unhealthy
Age Group: 26 - 42 years
Sex: M+F
Sources:
Disc. AE: Headache...
AEs leading to
discontinuation/dose reduction:
Headache (grade 2-5, 8 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache grade 2-5, 8 patients
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 26 - 42 years
Health Status: unhealthy
Age Group: 26 - 42 years
Sex: M+F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


Drug as perpetrator​Drug as victim
PubMed

PubMed

TitleDatePubMed
The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.
1992 Dec
Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.
1992 Nov
Entecavir, FTC, L-FMAU, LdT and others.
2003
Treatment of chronic hepatitis B in 2002.
2003
US FDA approves Emtriva (FTC).
2003 Aug
The continuing evolution of HIV therapy.
2003 Dec
Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients.
2003 Dec 1
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future.
2003 Dec 15
Anti-HIV drug updates--three drugs on the near horizon.
2003 Jan
Gateways to clinical trials.
2003 Jan-Feb
FTC (Emtriva) approved.
2003 Jul 25
Gateways to clinical trials.
2003 Jul-Aug
Gateways to clinical trials.
2003 Jun
Gateways to clinical trials. March 2003.
2003 Mar
New antiretroviral drugs.
2003 Mar
Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase.
2003 May
Once-a-day highly active antiretroviral therapy: a systematic review.
2003 May 1
Atazanavir (Reyataz) and emtricitabine (Emtriva) for HIV infection.
2003 Nov 10
Polysaccharide-based chiral phase under polar organic mode of elution in the determination of the enantiomeric purity of emtricitabine an anti-HIV analogue nucleoside.
2003 Nov 24
Three new drugs approved by FDA.
2003 Nov-Dec
FTC (emtricitabine, Emtriva).
2003 Oct
FDA notifications. NRTI Emtriva receives FDA approval.
2003 Oct
Gateways to clinical trials.
2003 Oct
Assessment of the relative potency of emtricitabine and lamivudine.
2003 Oct 1
Emtricitabine: a new treatment option for simplified antiretroviral therapy.
2003 Sep
Emtriva gets approval.
2003 Sep
Pharmacokinetics of antiretrovirals in pregnant women.
2004
Emtricitabine/tenofovir disoproxil fumarate.
2004
Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.
2004
New treatment of chronic hepatitis B.
2004
Emtricitabine/tenofovir disoproxil fumarate.
2004
[Approval of a new nucleoside. Component of complete once daily regimen].
2004 Apr 26
[Improved long-term success. New nucleoside for once daily combinations].
2004 Apr 26
New once-daily HIV combination better tolerated.
2004 Dec
Labeling changes for tenofovir.
2004 Jan
Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy.
2004 Jan
Gateways to clinical trials.
2004 Jun
Antiviral drugs in current clinical use.
2004 Jun
Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial).
2004 Mar
Gateways to clinical trials.
2004 May
Emtricitabine (FTC) for the treatment of HIV infection.
2004 May
[New approaches in the treatment of hepatitis B].
2004 May 21
Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection.
2004 Nov
Pharmacologic perspectives for once-daily antiretroviral therapy.
2004 Nov
A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.
2004 Nov 19
Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors).
2004 Nov-Dec
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
2004 Oct
HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches.
2004 Sep
New nucleoside/nucleotide backbone options: a review of recent studies.
2004 Sep 1
Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
2004 Sep 1
Patents

Sample Use Guides

Emtriva® (emtricitabine) dosage.
Route of Administration: Oral
emtricitabine EC50 0.99 μM (in vitro activity against HIV-2)
Substance Class Chemical
Created
by admin
on Fri Jun 25 23:59:29 UTC 2021
Edited
by admin
on Fri Jun 25 23:59:29 UTC 2021
Record UNII
G70B4ETF4S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EMTRICITABINE
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
524W91
Code English
EMTRICITABINE, (-)-
Common Name English
STRIBILD COMPONENT EMTRICITABINE
Brand Name English
EMTRICITABINE COMPONENT OF STRIBILD
Brand Name English
EVIPLERA COMPONENT EMTRICITABINE
Brand Name English
DESCOVY COMPONENT EMTRICITABINE
Common Name English
5-FLUORO-1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)CYTOSINE (2R,5S)
Common Name English
EMTRICITABINE COMPONENT OF DESCOVY
Common Name English
EMTRICITABINE COMPONENT OF TRUVADA
Brand Name English
EMTRICITABINE [USP-RS]
Common Name English
EMTRICITABINE COMPONENT OF GENVOYA
Brand Name English
DESCOVY COMPONENT OF EMTRICITABINE
Common Name English
TRUVADA COMPONENT EMTRICITABINE
Brand Name English
2(1H)-PYRIMIDINONE, 4-AMINO-5-FLUORO-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)-
Systematic Name English
EMTRIVA
Brand Name English
ATRIPLA COMPONENT EMTRICITABINE
Common Name English
(-)-EMTRICITABINE
Common Name English
FTC
Common Name English
ODEFSEY COMPONENT EMTRICITABINE
Brand Name English
EMTRICITABINE [MART.]
Common Name English
COVIRACIL
Brand Name English
EMTRICITABINE [MI]
Common Name English
EMTRICITABINE [EMA EPAR]
Common Name English
EMTRICITABINE COMPONENT OF ODEFSEY
Brand Name English
EMTRICITABINE [VANDF]
Common Name English
EMTRICITABINE [ORANGE BOOK]
Common Name English
5-FLUORO-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)CYTOSINE
Systematic Name English
BIKTARVY
Brand Name English
EMTRICITABINE COMPONENT OF EVIPLERA
Brand Name English
EMTRICITABINE [JAN]
Common Name English
524-W-91
Code English
EMTRICITABINE [HSDB]
Common Name English
EMTRICITABINE [USAN]
Common Name English
FTC-(-)
Code English
EMTRICITABINUM [WHO-IP LATIN]
Common Name English
EMTRICITABINE COMPONENT OF ATRIPLA
Common Name English
EMTRICITABINE [WHO-IP]
Common Name English
EMTRICITABINE [WHO-DD]
Common Name English
(-)-FTC
Common Name English
BW-524W91
Code English
EMTRICITABINE [INN]
Common Name English
(2R-CIS)-4-AMINO-5-FLUORO-1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)-2(1H)-PYRIMIDINONE
Systematic Name English
Classification Tree Code System Code
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (FTC/TEN)
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (EFV/FTC/TEN)
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
EMA ASSESSMENT REPORTS TRUVADA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
EMA ASSESSMENT REPORTS EMTRIVA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AF09
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-VATC QJ05AR09
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
EMA ASSESSMENT REPORTS DESCOVY (AUTHORIZED: HIV INFECTIONS )
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
FDA ORPHAN DRUG 569716
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
NCI_THESAURUS C1557
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AR18
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
NDF-RT N0000175462
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
NDF-RT N0000009947
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-VATC QJ05AR06
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
EMA ASSESSMENT REPORTS STRIBILD (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
EMA ASSESSMENT REPORTS EVIPLERA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
LIVERTOX 346
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-VATC QJ05AR08
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
EMA ASSESSMENT REPORTS ATRIPLA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AR09
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
EMA ASSESSMENT REPORTS GENVOYA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-VATC QJ05AF09
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AR06
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AR03
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
FDA ORPHAN DRUG 559316
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
NCI_THESAURUS C97452
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
EU-Orphan Drug EU/3/14/1420
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AR19
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-VATC QJ05AR03
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AR20
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.1
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AR17
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AR08
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
Code System Code Type Description
HSDB
7337
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
DRUG BANK
DB00879
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
EPA CompTox
143491-57-0
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
PUBCHEM
60877
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
NCI_THESAURUS
C47509
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
EVMPD
SUB01882MIG
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
INN
7822
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
MERCK INDEX
M4892
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY Merck Index
MESH
C122114
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
ChEMBL
CHEMBL885
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
FDA UNII
G70B4ETF4S
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
EMTRICITABINE
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY Description: White to almost white, crystalline powder. Solubility: Freely soluble in methanol R and water R, practically insoluble in dichloromethane R. Category: Antiretroviral (Nucleoside Reverse Transcriptase Inhibitor). Storage: Emtricitabine should be kept in a tightly closed container. Additional information: Emtricitabine may exhibit polymorphism.
DRUG CENTRAL
1003
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
CAS
143491-57-0
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
USP_CATALOG
1235106
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY USP-RS
LACTMED
Emtricitabine
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
WIKIPEDIA
EMTRICITABINE
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
RXCUI
276237
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY RxNorm
Related Record Type Details
TRANSPORTER -> INHIBITOR
TARGET -> INHIBITOR
IC50
RACEMATE -> ENANTIOMER
TRANSPORTER -> INHIBITOR
ENANTIOMER -> ENANTIOMER
BINDER->LIGAND
BINDING
Related Record Type Details
METABOLITE -> PARENT
About 4% of dose
MINOR
URINE
METABOLITE -> PARENT
9% of dose
MAJOR
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC